C56
Conditions
Interventions
Group 1: Using questionnaires and assessments (clock draw test, Stand uo and go test, handcraft test) a fragility score will be established
Sponsors
NOGGO e.V.
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Patients must provide written informed consent prior to performance of study specific assessments and must be willing to comply with recommended treatment and follow up assessments. • Able to complete questionnaires independently. • Women aged = 18 years • Histologically confirmed diagnosis of epithelial ovarian cancer or carcinosarcoma (EOC), primary peritoneal carcinoma (PPC) or fallopian tube cancer (FTC). • Patients must have recurrent cancer disease (CA 125, radiological or clinical signs of recurrence or progression). • Patients recommended for monochemotherapy with either Paclitaxel, PLD, Topotecan or Treosulfan and with optional use of bevacizumab according decision of the treating physician and following approval and who should start therapy within 2 week of registration in this trial. • At least 1 prior treatment regimen for ovarian cancer (i.e. up from second line treatment is allowed) • Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3 • A life expectancy of at least 12 weeks.
Exclusion criteria
Exclusion criteria: • Patients recommended for combination chemotherapy or under maintenance treatment after prior chemotherapy, or planned only for radiation therapy. • Chemotherapy or radiation therapy or tumour embolization within 2 weeks prior to registration and study assessment. • Biological therapy, immunotherapy, hormonal therapy or treatment with an investigational agent within 21 days. • Any unstable or serious concurrent condition (e.g. active infection requiring systemic therapy). • Legal incapacity or limited legal capacity • Medical or psychological conditions that would not permit the subject to complete the study assessments or sign informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score Evaluation and validation in two phases using questionnaires and assessments | — |
Secondary
| Measure | Time frame |
|---|---|
| • Adverse events • The time to symptom deterioration (TUDD) • Response rate (CR, PR) according to institutional criteria for evaluation (CT/MRI evaluation and / or GCIG criteria), and/or according deterioration or recovery of clinical symptoms • Progression free survival (PFS) and overall survival (OS) 12 months after start of therapy • The percentage of patients who complete 4 or more cycles of treatment • Associations between study assessments, symptom benefit, toxicity and their relation to therapy-free interval and outcome • The proportion of women who receive treatment because they were (a) symptomatic, (b) have rising tumor markers alone, or (c) have CT/MRI evidence of disease progression • Rate of emergency hospitalisation • Need for the use of ESF and G-CSF factors | — |
Countries
Germany
Contacts
Public ContactJalid Sehouli
Charité Campus Virchow-Klinikum
Outcome results
None listed